MedTrace Logo

Remifentanil/Sufentanil for CABG+/-AVR Evaluated by Recovery, Cognitive Function, Haemodynamics and Biochemical Markers.

NCT02053818 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2015-08-13

No results posted yet for this study

Summary

To evaluate the effect on cognitive function, recovery, cardioprotection and haemodynamics of standard Remifentanil anaesthesia to standard Sufentanil anaesthesia in patients undergoing coronary artery bypass with or without aortic valve replacement.

Conditions

  • Ischaemic Heart Disease
  • Aortic Stenosis

Interventions

DRUG

Remifentanil

Randomization to receive Remifentanil (ultrashort acting opioid) as basic opioid in anaesthesia

DRUG

Sufentanil

Randomization to receive Sufentanil (medium/long acting opioid) as basic opioid in anaesthesia

Sponsors & Collaborators

  • Aarhus University Hospital

    lead OTHER

Principal Investigators

  • Carl-Johan Jakobsen, MD · Department of Anaesthesiology and Intensive Care, Aarhus University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2015-06-30
Completion
2015-08-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02053818 on ClinicalTrials.gov